引用本文:张东卫.不同治疗剂量奥氮平对男性精神分裂症患者血糖血脂的影响[J].中国临床新医学,2015,8(3):228-231.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 1545次   下载 1087 本文二维码信息
码上扫一扫!
分享到: 微信 更多
不同治疗剂量奥氮平对男性精神分裂症患者血糖血脂的影响
张东卫
453002 河南,新乡医学院第二附属医院精神科
摘要:
[摘要] 目的 探讨不同治疗剂量奥氮平对男性精神分裂症患者血糖、血脂的影响。方法 选择60例男性精神分裂症患者随机分为两组,分别给予5~15 mg/d(低剂量组)和16~25 mg/d(高剂量组)治疗,于治疗前、治疗28 d后测量体重、血糖及血脂水平,同时用阳性症状和阴性症状量表(PANSS)评估精神症状。结果 与治疗前相比,治疗28 d后两组患者体重均显著增加(t=11.326,14.355),差异有统计学意义(P均<0.01)。治疗后两组间比较体重增加差异无统计学意义。与治疗前相比,治疗后两组患者总胆固醇(total cholesterol,TCH)和甘油三酯(triglyceride,TG)水平均明显升高,差异有统计学意义(P<0.01),血糖和高密度脂蛋白(HDL)水平变化不明显,差异无统计学意义(P>0.05)。两组治疗后比较血糖、血脂指标差异无统计学意义(P>0.05)。与治疗前相比,治疗后两组PANSS量表分值均明显降低,差异有统计学意义(P<0.01)。两组患者治疗后PANSS量表分值差异无统计学意义(P>0.05)。结论 奥氮平可导致男性精神分裂症患者血脂和体重增加,可能与治疗剂量无关。
关键词:  奥氮平  男性  精神分裂症  血糖  血脂
DOI:10.3969/j.issn.1674-3806.2015.03.10
分类号:R 749.3
基金项目:
Effects of different doses of olanzapine on blood glucose and lipids in male schizophrenic patients
ZHANG Dong-wei
Department of Psychiatry, the Second Affiliated Hospital of Xinxiang Medical University, Henan 453002, China
Abstract:
[Abstract] Objective To explore the effects of different doses of olanzapine treatment on blood glucose and lipids in male schizophrenics.Methods Sixty male schizophrenic patients were divided into two groups randomly and olanzapine were given at 5~15 mg per day(low dose group) and 16~25 mg per day(high dose group). Weight, blood glucose and lipids were measured before treatment and after 28 days′ treatment meanwhile PANSS was used to assess the psychological symptoms.Results Weight gains in the two groups were significant after treatment(t=11.326, 14.355) and there were significant differences(P<0.01). There was no significant difference in weight gains between groups after treatment. The serum levels of total cholesterol(TCH) and triglyceride(TG) in the two groups after treatment were increased than those before treatment and there were significant differences(P<0.01), but there was no significant difference between two groups after treatment. Compared before treatment, there was no significant difference in the levels of glucose and high density lipoprotein-cholesterol(HDL) in the two groups after treatment and there was no significant difference between the two groups(P>0.05). Compared before treatment, the total scores of PANSS in the two groups were decreased after treatment and there were significant differences(P<0.01), but there was no significant difference between two groups after treatment.Conclusion Olanzapine can increase weight and the level of lipid in male schizoprenic patients and it may not be related with treatment dose.
Key words:  Olanzapine  Male  Schizophrenia  Blood glucose  Blood lipid